deltatrials
Recruiting PHASE2 NCT04434040

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)

Sponsor: Dana-Farber Cancer Institute

Conditions Breast Cancer Circulating Tumor DNA Residual Cancer Triple Negative Breast Cancer
Interventions Atezolizumab Sacituzumab govitecan
Updated 17 times since 2020 Last updated: Aug 14, 2025 Started: Jul 2, 2020 Primary completion: Dec 30, 2026 Completion: Dec 30, 2027

A PHASE2 clinical study on Breast Cancer and Circulating Tumor DNA, this trial is actively recruiting participants. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 17 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  2. Nov 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Jul 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jun 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  3. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  4. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  5. Nov 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  6. Oct 2021 — Nov 2021 [monthly]

    Suspended PHASE2

  7. Jan 2021 — Oct 2021 [monthly]

    Suspended PHASE2

  8. Nov 2020 — Jan 2021 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  9. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  10. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  11. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Genentech, Inc.
  • Stand Up To Cancer
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Chicago, United States
  • • Nashville, United States
  • • New Lenox, United States
  • • Orland Park, United States
  • • Philadelphia, United States
  • • San Francisco, United States